SCHEMBL5201838

SCHEMBL5201838

Cc1ccc(NC(=O)c2ccc(Cn3c(=O)[nH]n(C)c3=O)cc2)cc1Nc1ncccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRA P16234 9/20 0.55
▸ ABL1 P00519 16/20 0.53
▸ KIT P10721 14/20 0.53
▸ BCR P11274 11/20 0.53
▸ ABL2 P42684 5/20 0.53
▸ PDGFRB P09619 3/20 0.53
▸ PLK4 O00444 1/20 0.53
▸ DDX3X O00571 1/20 0.53
▸ GAK O14976 1/20 0.53
▸ SLC22A2 O15244 1/20 0.53
▸ MAPK13 O15264 1/20 0.53
▸ CA12 O43570 1/20 0.53
▸ SLC22A3 O75751 1/20 0.53
▸ ABCB11 O95342 1/20 0.53
▸ EGFR P00533 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ ALB P02768 1/20 0.53
▸ RAF1 P04049 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5201739 0.89 PDGFRA (0.65) PDGFRAABL1KITBCRABL2
SCHEMBL5067293 0.88 PDGFRA (0.75) PDGFRAABL1KITBCRABL2
SCHEMBL14375891 0.81 PDGFRA (0.53) PDGFRAABL1KITBCRABL2
SCHEMBL5188124 0.79 ABL1 (0.53) PDGFRAABL1KITBCRABL2
SCHEMBL14375896 0.79 PDGFRA (0.55) PDGFRAABL1KITBCRABL2
SCHEMBL27640742 0.78 PDGFRA (0.64) PDGFRAABL1KITBCRABL2
SCHEMBL14375882 0.77 PDGFRA (0.51) PDGFRAABL1KITBCRABL2
SCHEMBL14375804 0.76 ALDH1A1 (0.64) PDGFRAABL1KITBCRABL2
SCHEMBL14375901 0.76 ABL1 (0.65) PDGFRAABL1KITBCRABL2
SCHEMBL14375894 0.72 ABL1 (0.44) PDGFRAABL1KITBCRABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 — — US disclosed
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 — — US disclosed
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 — — US disclosed
EP-1590344-A4 ANTI-CANCER MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2007-08-29 — — EP disclosed
EP-1590344-A2 ANTI-CANCER MEDICAMENTS Deciphera Pharmaceuticals, Inc. (US) 2005-11-02 — — EP disclosed
US-20040176395-A1 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC 2004-09-09 — — US disclosed
WO-2004060305-A2 ANTI-CANCER MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2004-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176395-A1 Anti-cancer medicaments ABL1, ABL2, SRC PDGFRA 565/4885ABL1 1/4885KIT 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback